Proof of Concept Study Evaluating the Efficacy and Safety of ATH-063 Treatment in Patients With Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis (UC)

Study acronym: Aegean
StatusRecruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment opened
    • Study sites: 2 to 4
    • Start date changed from estimate of Jun 2026 to Apr 30, 2026
    • Eligibility criteria expanded, about 45 words
  2. Study sites: 0 to 2
    • Start date: May 2026 to Jun 2026
    v2
  3. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The primary objective of this trial is to evaluate the clinical efficacy of ATH-063 in participants with biologic/advanced therapy relapsed/refractory moderately to severely active UC.
Trial Details
NCT Number NCT07513181
Lead Sponsor Athos Therapeutics Inc
Conditions
(from sponsor)		 Ulcerative Colitis, Inflammatory Bowel Diseases, Autoimmune Diseases
Related terms Autoimmune Diseases, Colitis, Colitis, Ulcerative, Inflammatory Bowel Diseases, Ulcer
Enrollment 120 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov